A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
Latest Information Update: 05 Jan 2026
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 04 Dec 2025 Actual primary completion date changed from 16 May 2025 to 9 Jun 2025.
- 13 Nov 2025 Status changed from active, no longer recruiting to discontinued.
- 03 Sep 2025 Status changed from suspended to active, no longer recruiting.